(NASDAQ: MGX) Metagenomi's forecast annual revenue growth rate of -13.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Metagenomi's revenue in 2025 is $33,768,000.On average, 3 Wall Street analysts forecast MGX's revenue for 2025 to be $1,142,358,527, with the lowest MGX revenue forecast at $1,088,460,944, and the highest MGX revenue forecast at $1,225,081,559.
In 2026, MGX is forecast to generate $1,124,342,622 in revenue, with the lowest revenue forecast at $758,169,347 and the highest revenue forecast at $1,501,325,440.